Dexamethasone

Should be taken with food.

Systemic fungal infections; systemic infection unless being treated with specific anti-infectives. Perforation of drum membrane (otic). Administration of live virus vaccine.

Patients with hypertension, acute MI, heart failure, diabetes mellitus, gastrointestinal diseases (e.g. diverticulitis intestinal anastomoses, active or latent peptic ulcer ulcerative colitis); ocular diseases (e.g. cataracts, glaucoma, history of ocular herpes simplex); osteoporosis, history of seizure disorder, thyroid disease. Renal and hepatic impairment. Elderly. Children. Pregnancy and lactation. Avoid abrupt withdrawal or rapid dose reduction. Ophth: This drug may cause blurring of vision, if affected, do not drive or operate machinery. Remove contact lenses prior to ophthalmic administration and reinsert after 15 minutes. Monitoring Parameters Monitor growth for children and intraocular pressure.

Significant: Adrenal suppression (e.g. hypercortisolism, suppression of hypothalamic-pituitary-adrenal [HPA] axis); Kaposi sarcoma; myopathy; perineal irritation, psychiatric disturbance, immunosuppression (e.g. secondary infections, activation of latent infections, mask acute infection); increased intra-ocular pressure, open-angle glaucoma and cataracts. Rarely, anaphylactoid reactions. Endocrine disorders Growth retardation in children. Eye disorders: Bacterial keratitis, eye irritation and pruritus, burning sensation, ocular discomfort. General disorders and administration site conditions: Impaired wound healing. Investigations: Weight gain. Metabolism and nutrition disorders: Cushing's syndrome, obesity. Musculoskeletal and connective tissue disorders: Osteoporosis. Nervous system disorders: Headache, muscle atrophy. Psychiatric disorders: Euphoria, depression, suicidal tendencies. Skin and subcutaneous tissue disorders: Skin fragility.

Decreased plasma concentration with CYP3A4 inducers (e.g. barbiturates, carbamazepine, ephedrine, phenytoin, rifabutin, rifampicin). Increased plasma concentration with CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, ritonavir). May increase renal clearance of salicylates. May enhances hypokalaemic effects of diuretics (acetazolamide, loop, thiazide), amphotericin B injection, corticosteroids, carbenoxolone, and K-depleting agents. May enhance anticoagulant effect of warfarin.

Corticosteroid Hormones / Ear Corticosteroids / Eye Corticosteroids

C05AA09 - dexamethasone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
H02AB02 - dexamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
D10AA03 - dexamethasone ; Belongs to the class of topical corticosteroids used in the treatment of acne.
S01BA01 - dexamethasone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
S02BA06 - dexamethasone ; Belongs to the class of corticosteroids used in the treatment of inflammation of the ear.
A01AC02 - dexamethasone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
D07XB05 - dexamethasone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
S03BA01 - dexamethasone ; Belongs to the class of corticosteroids used in ophthalmologic and otologic preparations.
D07AB19 - dexamethasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
S01CB01 - dexamethasone ; Belongs to the class of corticosteroids/antiinfectives/mydriatics combinations. Used in the treatment of eye diseases.
R01AD03 - dexamethasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.